September 1, 2024Open Access

Impact of PROphet Test in Changing Physicians' Therapeutic Decision-Making for Checkpoint Immunotherapy in Non–Small-Cell Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Immune Checkpoint Inhibitor (ICI) regimens are approved for first-line treatment of metastatic nononcogene-driven NSCLC. Guidelines do not differentiate which patients with PD-L1 ≥ 50% should receive ICI monotherapy. The clinically validated PROphet NSCLC plasma proteomic-based test is designed to inform this therapeutic decision.

Read Full Paperexternally

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Gandara et al. (Sun,) studied this question.

synapsesocial.com/papers/68e59e8eb6db643587538689 https://doi.org/https://doi.org/10.1016/j.cllc.2024.06.011

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer2024 · 18 citations
2Impact of Immunoscore on the Management of Stage II Colon Cancer Patients: A Physician Survey2021 · 4 citations
3Lung cancer immunotherapy: progress, pitfalls, and promises2023 · 1,031 citations
4Confidence intervals for a ratio of binomial proportions based on paired data2005 · 39 citations
5The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors2019 · 973 citations

Perguntar à IA

Bookmark

View Full Paper